The White House today announced landmark drug pricing agreements with Eli Lilly and Company and Novo Nordisk to lower the ...

Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...

Demand for popular weight loss drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound) has long outpaced supply, forcing many patients with obesity to visit compounding pharmacies to get ...

People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...

Such conversations are becoming increasingly common as demand for weight-loss drugs explodes in urban India - a country with ...

Macter International Limited (PSX: MACTER) has launched Semaglutide in Pakistan in Pre-Filled Syringe (PFS) and Pre-Filled ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...